Showing 2541-2550 of 9943 results for "".
When and How to Use Ancillary Testing
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/when-and-how-to-use-ancillary-testing/35598/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses when a dermatopathologist decides to use ancillary testing for melanoma, how that impacts final diagnosis, and how it can guide treatment decisions.The Importance and Utility of GEP Testing
https://practicaldermatology.com/series/updates-in-skin-cancer/the-importance-and-utility-of-gep-testing/35597/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses gene expression profiling technology and its importance in the diagnosis and prognostication of melanomas.Journal Club: Biologics for Young Children
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RNoah Worcester 2024: Dr. Webster on Isotretinoin
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-webster-isotretinoin/24581/Guy Webster, MD, PhD, FAAD, summarizes his lecture on new developments in isotretinoin at the 2024 Noah Worcester Dermatological Society meeting.Noah Worcester 2024: AAD President Dr. Desai on the AAD
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-desai-aad/24589/Seemal Desai, MD, FAAD, president of the American Academy of Dermatology, summarizes his AAD update presentation at the 2024 Noah Worcester Dermatological Society meeting.James Del Rosso, DO: Thoughts on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/james-del-rosso-do-thoughts-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24173/James Q. Del Rosso, DO, a dermatologist and president of The American Acne and Rosacea Society (AARS), weighs in on a recent report from Valisure which finds that benzene can form at elevated levels in products for acne that contain benzoyl peroxide (BPO). The interview was conducted by Neal Bhatia,DermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addresDermWireTV: ASDS Meeting Highlights; Daxxify Data; PA Week
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-asds-meeting-highlights-daxxify-data-pa-week/20147/ASDS speakers address aesthetic advancements, skin cancer, and DEI with Joel L. Cohen, MD, Sherrif Ibrahim, MD, and Jeanine Downie, MD. On the heels of FDA approval of Revance’s Daxxify, data published in the Aesthetic Surgery Journal demonstrate the efficacy of DaxibotulinumtoxinA for patients of dLiquid Rhinoplasty and Beyond: Injectable Pearls
https://practicaldermatology.com/series/scientifically-speaking/liquid-rhinoplasty-and-beyond-injectable-pearls/20008/From the best approach to safe and effective liquid nose corrections to tips for enhancing outcomes and streamline operations, Michael Somenek, MD; Kay Durairaj, MD; Shino Bay Aguilera, DO; and Corey Hartman, MD share their best tips with host Joel L. Cohen, MD.An Exciting Year in Dermatology
https://practicaldermatology.com/topics/psoriasis/an-exciting-year-in-dermatology/19929/From new topicals to novel systemic agents, several treatments may be coming to the market in the next two years, while existing therapies may see label expansions. Bruce Strober, MD, PhD offers a look at new MOAs and the evidence for their use.